Where is immatics located? From its research and development origins in Tübingen, Germany, to its cell therapy center in Houston, Texas and corporate functions in Munich, Germany, Immatics represents a trans-Atlantic team united to build a global leader in T cell receptor-based immunotherapies.Who is the ceo of immimmatics? Immatics will receive gross proceeds of up to $252 million at the closing of the transaction and will continue to operate under the Immatics management team headed by Chief Executive Officer Harpreet Singh, Ph.D. The respective boards of directors of both Arya and Immatics have approved the proposed transaction.Will immatics be listed on nasdaq? Immatics shareholders, Arya shareholders and PIPE investors will hold shares in the newly formed company with the name Immatics N.V. that is expected to be listed on NASDAQ under the ticker symbol “IMTX” Joint investor conference call to discuss the proposed transaction today, Tuesday, March 17, 2020 at 10:30 am ETWhat is genmabs deal with immatics? Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product concepts.
Harpreet Singh's Email. s*****@immatics.com Show email and phone number. Houston, Texas, United States. Co-Founder, Chief Scientific Officer, Managing Director @ Immatics Biotechnologies. President & CEO at Immatics US, Inc. @ Immatics Biotechnologies. Chief Executive Officer, Managing Director @ Immatics Biotechnologies.